TAK-341 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 17 | Multiple system atrophy | 2 |
17. Multiple system atrophy
Clinical trials : 119 / Drugs : 138 - (DrugBank : 44) / Drug target genes : 59 - Drug target pathways : 111
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2022-000336-28-DE (EUCTR) | 12/12/2022 | 28/07/2022 | A Study to evaluate Efficacy, Safety, Tolerability and Effects of TAK-341 in the human body in patients with Multiple System Atrophy | A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-341 in Subjects With Multiple System Atrophy | Multiple System Atrophy MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: TAK-341 Product Code: TAK-341 INN or Proposed INN: Not assigned Other descriptive name: Human IgG1 monoclonal antibody against alpha-synuclein | Takeda Development Center Americas, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 138 | Phase 2 | United Kingdom;Italy;Japan;Denmark;Austria;Germany;Portugal;France;United States;Spain | ||
| 2 | NCT05526391 (ClinicalTrials.gov) | November 9, 2022 | 1/9/2022 | A Study of TAK-341 in Treatment of Multiple System Atrophy | A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-341 in Subjects With Multiple System Atrophy | Multiple System Atrophy | Drug: TAK-341;Drug: Placebo | Takeda | AstraZeneca | Recruiting | 40 Years | N/A | All | 138 | Phase 2 | United States;Austria;Denmark;France;Germany;Italy;Japan;Portugal;Spain;United Kingdom |